Breaking News
July 23, 2018 - No Outcome Differences Based on Anesthesia Team Make-Up
July 23, 2018 - Getting to the heart of congenital cardiac defects
July 23, 2018 - Healthy behaviors are not effective in preventing gestational diabetes in obese women
July 23, 2018 - Top of Teachers’ To-Do List: Focus on the Positives
July 23, 2018 - LDL quality is a novel, modifiable cardiovascular risk marker
July 22, 2018 - Researchers identify enzyme as potential new drug target for blood disorders
July 22, 2018 - Research shows that neurons can encode more than one signal at a time
July 22, 2018 - Exposure to secondhand smoke increases the risk of stillbirth
July 22, 2018 - Skin conditions by the numbers
July 22, 2018 - Brain tumour chemotherapy now available to even more NHS patients
July 22, 2018 - Researchers find mugwort pollen as major source of airborne endotoxins
July 22, 2018 - Occupational safety and health at workplace
July 22, 2018 - Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
July 22, 2018 - Early supper associated with lower risk of breast and prostate cancer
July 22, 2018 - Survey results identify major inequalities in acute stroke treatment across Europe
July 22, 2018 - Researchers discover promising treatment for genetic form of autism spectrum disorder
July 22, 2018 - Prenatal Depression More Common in Young Moms Today
July 22, 2018 - What helps adults with autism get and keep a job?
July 22, 2018 - Pediatric NEXUS Head CT DI guides selective imaging decisions in blunt trauma patients
July 22, 2018 - Novel tool predicts genes that cause disease due to production of truncated proteins
July 22, 2018 - AHA: Vaping Tied to Blood Clots — in Mice
July 22, 2018 - Study finds therapy dogs effective in reducing symptoms of ADHD
July 22, 2018 - Scientists find reason why malarial parasites are faster than immune cells
July 22, 2018 - Researchers gain more insight into how FUS protein causes ALS and FTLD
July 22, 2018 - Frequency of joint replacements halved in rheumatoid arthritis patients between 1997-2010
July 22, 2018 - QUT researcher highlights growing impact of non-prescription antibiotics supply in pharmacies
July 22, 2018 - UK health communication researcher seeks solutions for disposing leftover medicine
July 22, 2018 - Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy Fidanacogene Elaparvovec
July 22, 2018 - Mutation discovered to protect against Alzheimer’s disease in mice
July 22, 2018 - Researchers reveal how patients in urban areas develop multiple, long-term conditions
July 22, 2018 - Replacing conventional cancer treatment with complementary therapy linked to increased risk of death
July 22, 2018 - Study uncovers molecular key for delaying progression of multiple sclerosis
July 22, 2018 - Availability of athletic trainer in high school reduces injury rates in girls’ sports, shows study
July 22, 2018 - FDA Approves Krintafel (tafenoquine) for the Radical Cure of Plasmodium vivax Malaria
July 22, 2018 - Novel nuclear medicine probe will help assess new drugs for neurodegenerative diseases
July 22, 2018 - Physical activity even during exposure to air pollution can reduce risk of heart attack
July 22, 2018 - Scientists discover protein regulator of myelin production
July 22, 2018 - Sleep disturbances associated with higher dementia risk
July 22, 2018 - Scientists move one step further in developing eye drops to treat age-related macular degeneration
July 22, 2018 - Five-Year Stroke Rates Lower After PCI Versus CABG
July 21, 2018 - Alopecia areata – Genetics Home Reference
July 21, 2018 - Study identifies overdose risk factors in youth with substance use disorders
July 21, 2018 - Drug in clinical trials for Parkinson’s disease offers hope for treating heart failure
July 21, 2018 - Coupling free malaria tests with diagnosis-dependent vouchers can improve rational use of ACTs
July 21, 2018 - Sweetness depends on molecular interactions between specific sugars and water in saliva
July 21, 2018 - Muscle fitness is strongly associated with improved rate of ageing in the brain
July 21, 2018 - Resetting E-Prescriptions for Opioids Helps Curb Use: Study
July 21, 2018 - Overuse of antibiotics not what the doctor ordered
July 21, 2018 - Bundled-payment system did not lower costs for serious medical conditions, shows study
July 21, 2018 - Therapy dogs found to be effective in reducing ADHD symptoms in children
July 21, 2018 - Could rotating multiple therapists better treat PTSD patients?
July 21, 2018 - Binge drinking impairs working memory in adolescent brain
July 21, 2018 - Dying at home could be beneficial for terminally ill cancer patients and their relatives
July 21, 2018 - Researchers identify subtypes of retinal ganglion cells using single-cell RNA sequencing
July 21, 2018 - Study uncovers opportunities to reduce death by suicide among cancer patients
July 21, 2018 - Genetic sequencing reveals new clues to aggressiveness of prostate cancer
July 21, 2018 - BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia
July 21, 2018 - First major study comparing robotic to open surgery published in The Lancet
July 21, 2018 - ADHD medications may fail to improve cognition in healthy college students, study shows
July 21, 2018 - Intervention program that includes a personalized app could benefit teens with suicidal thoughts
July 21, 2018 - Researchers identify new compound that protects against neurodegeneration
July 21, 2018 - Gene therapy may hold potential to treat people with spinal cord injuries
July 21, 2018 - FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen
July 21, 2018 - Surgeons have substantial impact on genetic testing in breast cancer patients who need it
July 21, 2018 - Species diversity can have positive and negative impacts on disease transmission
July 21, 2018 - Genome research suggests presence of enteric fever in medieval Europe
July 21, 2018 - Risk of Sensory Deficits Drops With Rising Gestational Age
July 21, 2018 - Mum’s sleep matters—the effect of sleep on an unborn baby
July 21, 2018 - UC San Diego researchers awarded two grants for investigating stem cell-based therapies
July 21, 2018 - Cellular ‘garbage disposal’ may actually work on some of the proteins to neuronal development
July 21, 2018 - More Pregnant Women Having Heart Attacks
July 21, 2018 - Acne Breakouts | NIH News in Health
July 21, 2018 - Change health messaging to focus on potential impact to help stop the next pandemic
July 21, 2018 - Frailty associated with poor survival rates in young heart patients
July 21, 2018 - New discovery could save millions of lives from fatal fungal infections
July 21, 2018 - OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes
July 21, 2018 - Childhood adversity increases susceptibility to addiction via immune response
July 21, 2018 - Scientists identify potential target for the treatment of binge eating
July 21, 2018 - Whole-brain LIPUS therapy improves cognitive dysfunction in mice simulating dementia, Alzheimer’s
July 21, 2018 - Digital media use raising risk of ADHD symptoms among the young
New SERM Shows Promise in Advanced Breast Cancer

New SERM Shows Promise in Advanced Breast Cancer

image_pdfDownload PDFimage_print

Action Points

  • In women with estrogen receptor-positive, hormone-refractory metastatic breast cancer, oral Z-endoxifen hydrochloride, the potent metabolite of tamoxifen, provided substantial drug exposure regardless of CYP2D6 genotype, acceptable toxicity, and promising antitumor activity.
  • Note that the study was unable to determine the maximum-tolerated dose of oral endoxifen, and dose escalation was discontinued at 160 mg per day and endoxifen concentrations >1,900 ng/mL.

In women with estrogen receptor-positive, hormone-refractory metastatic breast cancer, oral Z-endoxifen hydrochloride, the potent metabolite of tamoxifen, provided substantial drug exposure regardless of CYP2D6 genotype, acceptable toxicity, and promising antitumor activity, researchers reported.

Results from a phase I study in 38 patients with metastatic breast cancer demonstrated a clinical benefit rate (stable disease ≥ 6 months) of 26.3%. including a partial response by RECIST criteria in three patients who experienced progression during prior tamoxifen therapy, according to Matthew P. Goetz, MD, of the Mayo Clinic in Rochester, Minnesota, and colleagues.

Clinical benefit was also seen in seven patients who had no prior tamoxifen treatment or who didn’t experience progression with adjuvant tamoxifen. The median progression-free survival (PFS) time was 110 days, with a 1-year PFS rate of 15%, they wrote online in the Journal of Clinical Oncology.

The study was unable to determine the maximum-tolerated dose of oral endoxifen, and dose escalation was discontinued at 160 mg per day and endoxifen concentrations >1,900 ng/mL. At the time of data lock on March 5, 2017, seven patients had died due to metastatic breast cancer. Of the 31 patients who were alive, two did not have disease progression and 29 did.

Notably, CYP2D6 — the enzyme that converts tamoxifen to endoxifen — was not associated with either Z-endoxifen oral clearance or PFS, the study showed.

Based on these results, “The relationship between CYP2D6 genotype, endoxifen exposure, and the antitumor benefit of both drugs will be evaluated in the randomized phase II trial of Z-endoxifen and tamoxifen,” authors wrote. The trial will directly compare endoxifen (80 mg/day) with tamoxifen (20 mg/day) in women with prior aromatase inhibitor (AI) progression.

For the current study, 41 women were enrolled from March 25, 2011 to Dec. 9, 2014, and 38 were included in the maximum-tolerated dose (MTD) determination. A total of 36 patients experienced progression while on an AI, 21 while on fulvestrant (Faslodex), and 15 progressed on prior tamoxifen therapy.

Patients received 20, 40, 60, 80, 100, 120, or 160 mg of Z-endoxifen by mouth daily or until unable to continue treatment. Dose levels 40, 80, and 100 mg/day were also studied in the expansion phase of the trial. Of the 16 patients enrolled in the expansion cohorts, six were randomized to 40 mg/day, five to 80 mg/day, and five to 100 mg/day.

Dose-limiting toxicities were reported in two patients at the 60-mg dose: a pulmonary embolus after one cycle of treatment and a grade 4 hypertriglyceridemia after five treatment cycles. No eye toxicity was observed and there were no adverse effects reported in the expansion cohorts.

“Long-term studies will be necessary to fully evaluate the adverse effect profile of Z-endoxifen,” the authors said.

Other selective ER modulators (SERMs) have been shown to reduce cholesterol levels and endoxifen appears to do the same. Preliminary results suggest this new SERM reduces both total and LDL cholesterol levels.

Patients with low CYP2D6 enzyme activity exhibit significantly lower endoxifen concentrations when treated with tamoxifen, Goetz’s group pointed out. Data from this study indicate that even non-therapeutic levels of Z-endoxifen can have antitumor activity in patients experiencing progression with tamoxifen, they said.

Patients with prior tamoxifen exposure and a CYP2D6 activity score ≥2.0 generally had rapid clinical progression with a shorter median PFS compared with patients with reduced CYP2D6 metabolism and an activity score ≤1.5 (61 vs 132 days, respectively, P=0.046).

In an accompanying editorial, V. Craig Jordan, PhD, of the MD Anderson Cancer Center in Houston, said that while the value of endoxifen as a salvage therapy will be determined in future clinical studies, “this could just be the beginning of a new era. Perhaps it is the right time to consider improving women’s health with a new SERM.”

More than 30 years ago, Jordan — known as the “Father of Tamoxifen” — discovered that the drug’s anti-estrogenic properties could halt breast cancer growth, thus paving the way for SERMs.

Although AIs are the current standard of care in postmenopausal women with breast cancer, the consequences of long-term therapy remain a concern, he noted.

“Improvements in the use of SERMs may be an important first step in creating an improved quality of life for an aging population,” suggested Jordan, noting that using adjuvant tamoxifen therapy for 10 years makes it possible “to save the lives of 50% of patients with ER-positive breast cancer.”

In addition to potentially reducing risk of breast cancer recurrence, a new SERM might also improve overall health in menopausal women by lowering risk of osteoporosis, coronary heart disease, and stroke without increasing the odds of endometrial cancer, Jordan pointed out.

“It is not just about being alive; it is about being well,” he wrote.

The study was funded by the Mayo Clinic, the Regis Foundation, Prospect Creek Foundation, the George M. Eisenberg Foundation for Chanties, and the National Cancer Institute.

Goetz disclosed relevant relationships with Eli Lilly, bioTheranostics, RNA Diagnostics, Eli Lilly, and Pfizer. Co-authors disclosed multiple relevant relationships with industry.

Jordan disclosed no relevant relationships with industry.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-10-31T09:30:00-0400

Tagged with:

About author

Related Articles